Hamburg, Germany, 14 November, 2016 – Jomaa Pharma GmbH today announced the presentation of the results of its recently completed clinical study In Gabon to treat acute malaria with its Non-Artemisinin-based Combination Therapy comprising fosmidomycin and piperaquine. The scientific paper was presented at the 65th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Atlanta, GA, United States, by Dr Ghyslain Mombo-Ngoma, the Principal Investigator of the study. The paper was entitled ”Efficacy and safety of fosmidomycin and piperaquine as Non-Artemisinin-based Combination Therapy for acute uncomplicated falciparum malaria – A Phase 2a uncontrolled open-label proof of concept study in adults and children in Gabon”.
Jomaa Pharma’s fosmidomycin-piperaquine combination therapy is one of the most promising Non-Artemisinin-based Combination Therapies, as has been demonstrated by the outcome of the recently completed study published in Atlanta today. In the open label, uncontrolled proof of concept study conducted in Gabon, 100 subjects were enrolled including 10 adults aged 15 to 60 years, 40 older children aged 5 to 14 years and 50 children aged one to five years. Fosmidomycin and piperaquine were administered orally over three days and resulted in 100% cure rates at the critical time points of 7, 28 and 63 days post-treatment.
Read the full press release as downloadable PDF: